




Technology Snapshot

Biomarkers "PromarkerD" (Diagnostics)

Diabetes is the fastest growing medical problem in the world today, and all regions of the planet are affected. Of global markets, the incidence of Diabetic Kidney Disease (DKD) is worst in the USA, but China and India are expected to overtake it in the near future.

According to the International Diabetes Federation there are 387 million people currently living with diabetes and that number will grow by 200 million in the next 20 years. Kidney disease is one of the major complications of diabetes, and its prevalence is growing at least at the same rate.

Diabetes



Total annual cost impact of diabetes in Australia - \$14.6 billion

International Diabetes Foundation 2014

The company believes the commercial potential is vast because PromarkerD is both versatile and adaptable. Critically, PromarkerD offers a prognostic (predictive) test in a market where there are *no currently available predictive tests*. Existing tests are only diagnostic, detecting disease only after clinical symptoms have started to appear.

The current gold standard urine-based test for DKD is not robust, with results differing simply by taking a walk around the block before being tested. In contrast, PromarkerD is also both a robust and sensitive diagnostic test. It can detect people with severe or mild kidney disease, and also detect individuals missed by the existing tests.

PromarkerD has the potential to be used on multiple platforms and in different areas:

- as a specialist diagnostic test run by clinical laboratories (laboratory developed test, LDT)
- as a standard clinical pathology laboratory assay produced by diagnostic companies (in vitro diagnostic, IVD)
- as a next generation test to monitor a patient's response to drug therapy and enable personalised medicine (companion diagnostic test, CDx)